Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription 16.09.2024 3 Am J Psychiatry 3 J Clin Psychopharmacol 2 Mol Psychiatry 1 Nat Genet 1 Neuropsychopharmacology 1 PLoS Biol 1 PLoS Genet 1 PLoS One 3 Psychiatry Res 4 Psychol Med 15 Schizophr Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Psychiatry

1. PARTANEN JJ, Happola P, Kampe A, Ahola-Olli A, et al
   High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
   Am J Psychiatry. 2024 Sep 12:appiajp20230744. doi: 10.1176/appi.ajp.20230744.
   PubMed         Abstract available
   
   
2. MORAN LV, Skinner JP, Shinn AK, Nielsen K, et al
   Risk of Incident Psychosis and Mania With Prescription Amphetamines.
   Am J Psychiatry. 2024 Sep 12:appiajp20230329. doi: 10.1176/appi.ajp.20230329.
   PubMed         Abstract available
   
   
3. BRAND BA, Sommer IE, Gangadin SS, Tanskanen A, et al
   Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
   Am J Psychiatry. 2024 Sep 12:appiajp20230850. doi: 10.1176/appi.ajp.20230850.
   PubMed         Abstract available
   
   

   
   J Clin Psychopharmacol

4. MITOMA R, Hirano S, Nakao T
   Successful Management of ECT-Resistant Interictal Psychosis With Clozapine: A Case Report.
   J Clin Psychopharmacol. 2024;44:527-528.
   PubMed        
   
   
5. DI LISI A, Pupo S, Menchetti M, Pelizza L, et al
   Antipsychotic Treatment in People at Clinical High Risk for Psychosis: A Narrative Review of Suggestions for Clinical Practice.
   J Clin Psychopharmacol. 2024;44:502-508.
   PubMed         Abstract available
   
   
6. FLANAGAN RJ, Obee SJ, Kim AHM, Every-Palmer S, et al
   Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations and the Clozapine/Norclozapine Ratio : Effect of Dose, Sex, and Cigarette Smoking.
   J Clin Psychopharmacol. 2024;44:492-501.
   PubMed         Abstract available
   
   

   
   Mol Psychiatry

7. GARCIA-SAN-MARTIN N, Bethlehem RAI, Mihalik A, Seidlitz J, et al
   Molecular and micro-architectural mapping of gray matter alterations in psychosis.
   Mol Psychiatry. 2024 Sep 12. doi: 10.1038/s41380-024-02724.
   PubMed         Abstract available
   
   
8. NANI JV, Muotri AR, Hayashi MAF
   Peering into the mind: unraveling schizophrenia's secrets using models.
   Mol Psychiatry. 2024 Sep 8. doi: 10.1038/s41380-024-02728.
   PubMed         Abstract available
   
   

   
   Nat Genet

9. YUAN K, Longchamps RJ, Pardinas AF, Yu M, et al
   Fine-mapping across diverse ancestries drives the discovery of putative causal variants underlying human complex traits and diseases.
   Nat Genet. 2024;56:1841-1850.
   PubMed         Abstract available
   
   

   
   Neuropsychopharmacology

10. BRAKATSELOS C, Polissidis A, Ntoulas G, Asprogerakas MZ, et al
    Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
    Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01977.
    PubMed         Abstract available
    
    

    
    PLoS Biol

11. ROHE T, Hesse K, Ehlis AC, Noppeney U, et al
    Multisensory perceptual and causal inference is largely preserved in medicated post-acute individuals with schizophrenia.
    PLoS Biol. 2024;22:e3002790.
    PubMed         Abstract available
    
    

    
    PLoS Genet

12. ALI D, Laighneach A, Corley E, Patlola SR, et al
    Direct targets of MEF2C are enriched for genes associated with schizophrenia and cognitive function and are involved in neuron development and mitochondrial function.
    PLoS Genet. 2024;20:e1011093.
    PubMed         Abstract available
    
    

    
    PLoS One

13. LIM MJH, Iyyalol R, Lee JWY, Martin-Iverson MT, et al
    Multi-modal and bi-directional effects of a synthetic Delta9-Tetrahydrocannabinol (THC) analogue, Nabilone, on spatio-temporal binding windows: Evidence from the projected hand illusion.
    PLoS One. 2024;19:e0309614.
    PubMed         Abstract available
    
    

    
    Psychiatry Res

14. KRISTENSEN TD, Mager FM, Ambrosen KS, Barber AD, et al
    Cognitive profiles across the psychosis continuum.
    Psychiatry Res. 2024;342:116168.
    PubMed         Abstract available
    
    
15. HSIEH KP, Liao WL, Ho PS, Lin JW, et al
    Association of antipsychotic formulations with sudden cardiac death in patients with schizophrenia: A nationwide population-based case-control study.
    Psychiatry Res. 2024;342:116171.
    PubMed         Abstract available
    
    
16. MORKVED N, Johnsen E, Kroken RA, Joa I, et al
    Childhood trauma types in relation to antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, randomized controlled study.
    Psychiatry Res. 2024;341:116169.
    PubMed         Abstract available
    
    

    
    Psychol Med

17. BRAMNESS JG, Hjorthoj C, Niemela S, Taipale H, et al
    Discussing the concept of substance-induced psychosis (SIP).
    Psychol Med. 2024 Sep 10:1-5. doi: 10.1017/S0033291724001442.
    PubMed         Abstract available
    
    
18. GOLAY P, Abrahamyan Empson L, Mebdouhi N, Conchon C, et al
    Statistical implication analysis: a novel approach to understand the reciprocal relationships between outcomes in early psychosis.
    Psychol Med. 2024 Sep 9:1-6. doi: 10.1017/S0033291724001430.
    PubMed         Abstract available
    
    
19. KRUGER E, Hall L, Martinez AP, Bentall RP, et al
    Cognitive behavioral self-help interventions for individuals experiencing psychosis: a systematic review.
    Psychol Med. 2024 Sep 9:1-11. doi: 10.1017/S0033291724001545.
    PubMed         Abstract available
    
    
20. MARCHAM L, Ellett L
    Exposure to green spaces and schizophrenia: a systematic review.
    Psychol Med. 2024 Sep 9:1-12. doi: 10.1017/S0033291724001533.
    PubMed         Abstract available
    
    

    
    Schizophr Res

21. SALVI V, Tripodi B, Cerveri G, Migliarese G, et al
    Insulin-resistance as a modifiable pathway to cognitive dysfunction in schizophrenia: A systematic review.
    Schizophr Res. 2024;274:78-89.
    PubMed         Abstract available
    
    
22. ARORA S, Suhas S, Gowda GS, Reddi VSK, et al
    DRESS syndrome, seizures, and myocarditis on low dose clozapine - A case report.
    Schizophr Res. 2024;271:391-393.
    PubMed        
    
    
23. SARPAL DK
    Astrocytic contributions to clozapine response: Potential support for a psychopharmacologic glial process.
    Schizophr Res. 2024;271:142-143.
    PubMed        
    
    
24. GONZALO-DE MIGUEL A, Abascal-Peiro S, Cegla-Schvartzman FB, Martinez-Ales G, et al
    Antipsychotic use in a large community sample of patients with delusional disorder.
    Schizophr Res. 2024;271:194-199.
    PubMed         Abstract available
    
    
25. HARVEY PD, Davidson M, Saoud JB, Kuchibhatla R, et al
    Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria.
    Schizophr Res. 2024;271:246-252.
    PubMed         Abstract available
    
    
26. TERENZI D, Silvetti M, Zoccolan G, Rumiati RI, et al
    The impact of subclinical psychotic symptoms on delay and effort discounting: Insights from behavioral, computational, and electrophysiological methods.
    Schizophr Res. 2024;271:271-280.
    PubMed         Abstract available
    
    
27. SMUCNY J, Wood A, Davidson IN, Carter CS, et al
    Are factors that predict conversion to psychosis associated with initial transition to a high risk state? An adolescent brain cognitive development study analysis.
    Schizophr Res. 2024;272:128-132.
    PubMed         Abstract available
    
    
28. GREENWAY FT, Weal M, Palmer-Cooper EC
    Hybrid mHealth care: Patient perspectives of blended treatments for psychosis. A systematic review.
    Schizophr Res. 2024;274:1-10.
    PubMed         Abstract available
    
    
29. ALESSANDRO DL, Leuci E, Quattrone E, Azzali S, et al
    Obsessive-compulsive symptoms in individuals at clinical high risk for psychosis: A 2-year longitudinal study.
    Schizophr Res. 2024;274:11-20.
    PubMed         Abstract available
    
    
30. STARZER M, Hansen HG, Hjorthoj C, Albert N, et al
    Long-term quality of life and social disconnection 20 years after a first episode psychosis, results from the 20-year follow-up of the OPUS trial.
    Schizophr Res. 2024;274:33-45.
    PubMed         Abstract available
    
    
31. THOMPSON JL, Silverstein SM, Papathomas TV, Keane BP, et al
    Hallucinations and the depth-inversion illusion in schizophrenia.
    Schizophr Res. 2024;274:21-23.
    PubMed        
    
    
32. KRAMER M, Fink F, Campo LA, Akinci E, et al
    Video analysis of interaction in schizophrenia reveals functionally relevant abnormalities.
    Schizophr Res. 2024;274:24-32.
    PubMed         Abstract available
    
    
33. RAJ V, Stogios N, Agarwal SM, Cheng AJ, et al
    The neuromuscular basis of functional impairment in schizophrenia: A scoping review.
    Schizophr Res. 2024;274:46-56.
    PubMed         Abstract available
    
    
34. HORAN WP, Targum SD, Claxton A, Kaul I, et al
    Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
    Schizophr Res. 2024;274:57-65.
    PubMed         Abstract available
    
    
35. LEE R, Griffiths SL, Gkoutos GV, Wood SJ, et al
    Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model.
    Schizophr Res. 2024;274:66-77.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.